Activation of the cGAS/STING Axis in Genome-Damaged Hematopoietic Cells Does Not Impact Blood Cell Formation or Leukemogenesis

Cancer Res. 2023 Sep 1;83(17):2858-2872. doi: 10.1158/0008-5472.CAN-22-3860.

Abstract

Genome damage is a main driver of malignant transformation, but it also induces aberrant inflammation via the cGAS/STING DNA-sensing pathway. Activation of cGAS/STING can trigger cell death and senescence, thereby potentially eliminating genome-damaged cells and preventing against malignant transformation. Here, we report that defective ribonucleotide excision repair (RER) in the hematopoietic system caused genome instability with concomitant activation of the cGAS/STING axis and compromised hematopoietic stem cell function, ultimately resulting in leukemogenesis. Additional inactivation of cGAS, STING, or type I IFN signaling, however, had no detectable effect on blood cell generation and leukemia development in RER-deficient hematopoietic cells. In wild-type mice, hematopoiesis under steady-state conditions and in response to genome damage was not affected by loss of cGAS. Together, these data challenge a role of the cGAS/STING pathway in protecting the hematopoietic system against DNA damage and leukemic transformation.

Significance: Loss of cGAS/STING signaling does not impact DNA damage-driven leukemogenesis or alter steady-state, perturbed or malignant hematopoiesis, indicating that the cGAS/STING axis is not a crucial antioncogenic mechanism in the hematopoietic system. See related commentary by Zierhut, p. 2807.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Hematopoiesis / genetics
  • Interferon Type I* / metabolism
  • Leukemia* / genetics
  • Mice
  • Nucleotidyltransferases / genetics
  • Nucleotidyltransferases / metabolism
  • Signal Transduction

Substances

  • Interferon Type I
  • Nucleotidyltransferases
  • Sting1 protein, mouse
  • cGAS protein, mouse